184 related articles for article (PubMed ID: 11254385)
1. Structure and functionality of a designed p53 dimer.
Davison TS; Nie X; Ma W; Lin Y; Kay C; Benchimol S; Arrowsmith CH
J Mol Biol; 2001 Mar; 307(2):605-17. PubMed ID: 11254385
[TBL] [Abstract][Full Text] [Related]
2. A meanfield approach to the thermodynamics of a protein-solvent system with application to the oligomerization of the tumor suppressor p53.
Noolandi J; Davison TS; Volkel AR; Nie X; Kay C; Arrowsmith CH
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):9955-60. PubMed ID: 10944184
[TBL] [Abstract][Full Text] [Related]
3. Oxidation of methionine residue at hydrophobic core destabilizes p53 tetrameric structure.
Nomura T; Kamada R; Ito I; Chuman Y; Shimohigashi Y; Sakaguchi K
Biopolymers; 2009 Jan; 91(1):78-84. PubMed ID: 18781628
[TBL] [Abstract][Full Text] [Related]
4. Tandem dimerization of the human p53 tetramerization domain stabilizes a primary dimer intermediate and dramatically enhances its oligomeric stability.
Poon GM; Brokx RD; Sung M; Gariépy J
J Mol Biol; 2007 Jan; 365(4):1217-31. PubMed ID: 17113101
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
6. Solvent-exposed residues located in the beta-sheet modulate the stability of the tetramerization domain of p53--a structural and combinatorial approach.
Mora P; Carbajo RJ; Pineda-Lucena A; Sánchez del Pino MM; Pérez-Payá E
Proteins; 2008 Jun; 71(4):1670-85. PubMed ID: 18076077
[TBL] [Abstract][Full Text] [Related]
7. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function.
Lubin DJ; Butler JS; Loh SN
J Mol Biol; 2010 Jan; 395(4):705-16. PubMed ID: 19913028
[TBL] [Abstract][Full Text] [Related]
8. Latent and active p53 are identical in conformation.
Ayed A; Mulder FA; Yi GS; Lu Y; Kay LE; Arrowsmith CH
Nat Struct Biol; 2001 Sep; 8(9):756-60. PubMed ID: 11524676
[TBL] [Abstract][Full Text] [Related]
9. Oligomerization of p53 is necessary to inhibit its transcriptional transactivation property at high protein concentration.
Kristjuhan A; Jaks V; Rimm I; Tooming T; Maimets T
Oncogene; 1998 May; 16(18):2413-8. PubMed ID: 9620560
[TBL] [Abstract][Full Text] [Related]
10. Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions.
Stavridi ES; Chehab NH; Caruso LC; Halazonetis TD
Protein Sci; 1999 Sep; 8(9):1773-9. PubMed ID: 10493578
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome.
Davison TS; Yin P; Nie E; Kay C; Arrowsmith CH
Oncogene; 1998 Aug; 17(5):651-6. PubMed ID: 9704931
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.
Bullock AN; Henckel J; Fersht AR
Oncogene; 2000 Mar; 19(10):1245-56. PubMed ID: 10713666
[TBL] [Abstract][Full Text] [Related]
13. Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain.
Mateu MG; Fersht AR
EMBO J; 1998 May; 17(10):2748-58. PubMed ID: 9582268
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of folding and assembly of a small tetrameric protein domain from tumor suppressor p53.
Mateu MG; Sánchez Del Pino MM; Fersht AR
Nat Struct Biol; 1999 Feb; 6(2):191-8. PubMed ID: 10048932
[TBL] [Abstract][Full Text] [Related]
15. Dimerization of the p53 oligomerization domain: identification of a folding nucleus by molecular dynamics simulations.
Chong LT; Snow CD; Rhee YM; Pande VS
J Mol Biol; 2005 Jan; 345(4):869-78. PubMed ID: 15588832
[TBL] [Abstract][Full Text] [Related]
16. Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat.
Gabizon R; Mor M; Rosenberg MM; Britan L; Hayouka Z; Kotler M; Shalev DE; Friedler A
Biopolymers; 2008; 90(2):105-16. PubMed ID: 18189286
[TBL] [Abstract][Full Text] [Related]
17. Identification of a function-specific mutation of clathrin heavy chain (CHC) required for p53 transactivation.
Ohata H; Ota N; Shirouzu M; Yokoyama S; Yokota J; Taya Y; Enari M
J Mol Biol; 2009 Dec; 394(3):460-71. PubMed ID: 19766654
[TBL] [Abstract][Full Text] [Related]
18. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of oligomeric stability by covalent linkage and its application to the human p53tet domain: thermodynamics and biological implications.
Poon GM
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1574-8. PubMed ID: 18031269
[TBL] [Abstract][Full Text] [Related]
20. The 7-amino-acid site in the proline-rich region of the N-terminal domain of p53 is involved in the interaction with FAK and is critical for p53 functioning.
Golubovskaya VM; Finch R; Zheng M; Kurenova EV; Cance WG
Biochem J; 2008 Apr; 411(1):151-60. PubMed ID: 18215142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
